Intuitive, online, simultaneous, and proportional myoelectric control over two degrees-of-freedom in upper limb amputees. IEEE Trans. Neural Syst. Rehabil. Eng. 22, 501–510 (2014). Article PubMed Google Scholar Amsuess, S. et al. Context-dependent upper limb prosthesis control for natural ...
This randomized clinical trial compares the effectiveness of a self-fitting over-the-counter hearing aid with remote support with an audiologist-fitted
Impact of molnupiravir treatment on patient-reported coronavirus disease 2019 (COVID-19) symptoms in the phase 3 MOVe-OUT trial: a randomized, placebo-controlled trial. Clin Infect Dis. Published online June 19, 2023. doi:10.1093/cid/ciad409PubMedGoogle ScholarCrossref 16. Hashimoto Y...
We thank the patients and families for their participation in this clinical trial; J. A. Perry for her support in banking and providing PDX material that was used in this study; O. Abdel-Wahab, B. L. Bowman and L. A. Miles for their critical review of the manuscript; the citizen-scie...
Carlo Donati,MD, is medical advisor at the directorate general, information system, at the Ministry of Health, Via Giorgio Ribotta, 5, I-00144 Rome, Italy, email:c.donati@sanita.it. References 1. Europe's Information Society Thematic Portal, "Health: Better Healthcare for Europe," http://...
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Lancet, 387 (2016), pp. 545-557 doi:10.1016/S0140-6736(15)00986-1 View PDFView articleView in Scopus...
117, 118, 119, 120 In the context of strong clinical trial evidence from the interferon-ribavirin era that rituximab provides superior outcomes for cryoglobulinemic MPGN, the 2018 guideline recommends rituximab as a first-line option for patients who do not respond to antiviral therapy alone or ...
et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17, 883–895 (2016). Article CAS PubMed Google Scholar US Food and Drug Administration. FDA grants nivolumab accelerated ...
US patent no. 10921330. R.A. is a scientific advisor to Signant Health and consultant to Biogen. S.M. serves on the board of directors of Senscio Systems and the scientific advisory board of AiCure Technologies, and Boston Millennia Partners, and has received consulting fees from AARP, Bioge...
This platform randomized clinical trial examines the effectiveness of ivermectin at a targeted dose of 600 μg/kg daily compared with placebo for the